The study of the test's accuracy was conducted by researchers for Genomic Health, a company based in Redwood City, Calif., that developed the test, and the National Surgical Adjuvant Breast and Bowel Project, a federally financed group that conducts clinical trials.
A pilot study of the test-retest reliability of the questionnaire was conducted to demonstrate that the questionnaires were reliable (Kappa 0.83).
During this study, none of the tests was invalid.
In this study, none of the tests would survive Bonferroni correction.
The data from studies of the test are "unbelievably impressive," said Dr. Michael Birrer, an ovarian cancer specialist at Massachusetts General Hospital.
Structure activity relationship (SAR) studies of the test compounds were investigated based upon the in-vitro RT inhibitory potency.
In-vitro studies of the test compounds (5a-o), showed weak to moderate activity against HIV-1 RT (Table 1).
Safety studies of the tested molecules, as well as discovery of new CXCR2 antagonists are guaranteed.
The ROC curves provide the estimates for sensitivity and specificity, which is a commonly used evaluation metric in clinical studies, of the tested biomarker candidates.
FJW participated in the study design of the study, preparation of the tested material, performance of cell cultures, data analysis and wrote the manuscript.
